Cita APA

Borrás-Blasco, J., Valcuende-Rosique, A., Cornejo, S., Aparicio-Rubio, C., Aguilar-Zamora, M., Garijo-Bufort, M., & Arévalo-Ruales, K. (2024). Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.

Citación estilo Chicago

Borrás-Blasco, J., A. Valcuende-Rosique, S. Cornejo, C. Aparicio-Rubio, M. Aguilar-Zamora, M. Garijo-Bufort, y KR Arévalo-Ruales. Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases. 2024.

Cita MLA

Borrás-Blasco, J., et al. Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases. 2024.